FDA warned Malaysia-based website plakini-pharma.com for selling unapproved, misbranded opioids, benzodiazepines, and stimulants to U.S. consumers.
What happened
FDA reviewed the website www.plakini-pharma.com and found it offering unapproved and misbranded opioids, benzodiazepines, and Schedule II stimulants to U.S. consumers. The letter lists examples including fentanyl patches, hydrocodone, tramadol, oxycodone, Percocet, Dilaudid, Rohypnol/flunitrazepam, Adderall, and Ritalin. FDA said there are no approved applications for these products and their labeling lacks adequate directions for use.
What FDA found
The website offers opioids such as fentanyl, hydrocodone, tramadol, oxycodone, Percocet, and Dilaudid as new drugs without FDA-approved applications.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The website offers the benzodiazepine flunitrazepam (Rohypnol) as a new drug without an FDA-approved application.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The website offers Schedule II stimulants amphetamine (Adderall) and methylphenidate (Ritalin) as new drugs without FDA-approved applications.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The prescription drugs are offered with labeling that does not give adequate directions for safe use by a layperson.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]Offering these drugs for sale to U.S. consumers causes misbranded drugs to be introduced into interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]The website sells prescription drugs such as opioids and benzodiazepines without the prescription-supervision limits described in the law.
FD&C Act section 503(b) [21 U.S.C. § 353(b)]
What FDA wants
Within 15 working days, notify FDA in writing of steps taken to address the violations and prevent recurrence, or explain why the products are not in violation. FDA also requests that the website cease offering unapproved and misbranded drugs for sale to U.S. consumers.
Who should pay attention
- online pharmacies and websites selling to U.S. consumers
- companies that manage prescription drug labeling and sales
- quality and regulatory teams monitoring cross-border drug offers
This is a summary. Read the original letter on fda.gov.